RNS Number : 7801S
ValiRx PLC
09 January 2025

TR-1: Standard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS(to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)[i]

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached[ii]:	ValiRx PLC
1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)	
Non-UK issuer	
2. Reason for the notification(please mark the appropriate box or boxes with an "X")	
An acquisition or disposal of voting rights	X
An acquisition or disposal of financial instruments	
An event changing the breakdown of voting rights	
Other (please specify) [iii]:	
3. Details of person subject to the notification obligation[iv]	
Name	Mark Eccleston
City and country of registered office (if applicable)	UK
4. Full name of shareholder(s)(if different from 3.)[v]	
Name	
City and country of registered office (if applicable)	
5. Date on which the threshold was crossed or reached[vi]:	31/12/2024
6. Date on which issuer notified (DD/MM/YYYY):	08/01/2025

7. Total positions of person(s) subject to the notification obligation

	% of voting rights attached to shares (total of 8. A)	% ofvoting rights throughfinancial instruments (total of 8.B 1 + 8.B 2)	Total of both in % (8.A + 8.B)	Total number of voting rights held in issuer (8.A + 8.B)[vii]
Resulting situation on the date on which threshold was crossed or reached	6.08%		6.08%	22,746,187
Position of previous notification (if				

applicable)				

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached[viii]				
A: Voting rights attached to shares				
Class/type of shares ISIN code (if possible)	**Number of voting rights[ix]**		**% of voting rights**	
	Direct (DTR5.1)	**Indirect** (DTR5.2.1)	**Direct** (DTR5.1)	**Indirect** (DTR5.2.1)
GB00BLH13C52	15,592,341	7,153,846	4.17%	1.91%
SUBTOTAL 8. A	22,746,187		6.08%	

B 1: Financial Instruments according to DTR5.3.1R (1) (a)				
Type of financial instrument	**Expiration date[x]**	**Exercise/ Conversion Period[xi]**	**Number of voting rights that may be acquired if the instrument is exercised/converted.**	**% of voting rights**
		SUBTOTAL 8. B 1		

B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)					
Type of financial instrument	**Expiration date[x]**	**Exercise/ Conversion Period[xi]**	**Physical or cash Settlement[xii]**	**Number of voting rights**	**% of voting rights**
			SUBTOTAL 8.B.2		

9. Information in relation to the person subject to the notification obligation(please mark the applicable box with an "X")	
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer[xiii]	
Fullchain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary)[xiv]	X

Name[xv]	**% of voting rights if it equals or is higher than the notifiable threshold**	**% of voting rights through financial instruments if it equals or is higher than the notifiable threshold**	**Total of both if it equals or is higher than the notifiable threshold**

Mark Eccleston	4.17%		4.17%
OncoLytika Ltd	1.03%		1.03%
Annette Williams	0.88%		0.88%
Total	6.08%		6.08%

10.In case of proxy voting, please identify:	
Name of the proxy holder	
The number and % of voting rights held	
The date until which the voting rights will be held	

11. Additional information[xvi]
Further to the announcement on 30 December 2024, Mark Eccleston subscribed for 14,615,384 ordinary shares and OncoLytika Ltd subscribed for 3,846,154. Annette Williams's subscription remained unchanged. Mark Eccleston's aggregate subscription amount (including Annette Williams's) of £135k remains unchanged.

Place of completion	UK
Date of completion	08/01/2025

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

HOLUKOARVNUARAR